CD33 and acute myeloid leukemia: However, when engineered with CAR, CAR33-T cells demonstrated efficient killing of all CD33+ AML tumor cells while showing no cytotoxicity towards CD33- tumor cells, demonstrating their reliance on the CAR33-CD33 interaction (Fig. 3e and Supplementary Fig. 7a).